(Q40399993)

20 September 2017

1 reference

title

Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia (English)

1 reference

20 September 2017

1 reference

1 reference

B Fulton

1

1 reference

20 September 2017

A J Wagstaff

series ordinal

2

1 reference

20 September 2017

E M Sorkin

series ordinal

3

1 reference

20 September 2017

1 February 1995

1 reference

20 September 2017

1 reference

20 September 2017

49

1 reference

20 September 2017

295-320

1 reference

20 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199549020-00011

20 September 2017

0 references

cites work

Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension

1 reference

12 December 2020

Combination of nifedipine and doxazosin in essential hypertension

1 reference

12 December 2020

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups

1 reference

12 December 2020

Clinical pharmacological studies with doxazosin

1 reference

12 December 2020

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

12 December 2020

A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension

1 reference

12 December 2020

The antihypertensive effects of doxazosin: a clinical overview

1 reference

12 December 2020

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

1 reference

12 December 2020

Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers

1 reference

12 December 2020

The pharmacokinetics of doxazosin in patients with hypertension and renal impairment

1 reference

12 December 2020

Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents

1 reference

12 December 2020

Placebo-Controlled Trial of Doxazosin in Management of Patients with Hypertension and Hypercholesterolaemia

1 reference

12 December 2020

The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.

1 reference

12 December 2020

The metabolism and kinetics of doxazosin in man, mouse, rat and dog.

1 reference

12 December 2020

A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy

1 reference

12 December 2020

Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension

1 reference

12 December 2020

Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs

1 reference

12 December 2020

Concentration-effect relationships and individual responses to doxazosin in essential hypertension

1 reference

12 December 2020

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

1 reference

12 December 2020

Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function.

1 reference

12 December 2020

Doxazosin in the treatment of mild or moderate essential hypertension: An echocardiographic study

1 reference

12 December 2020

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.

1 reference

12 December 2020

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

12 December 2020

Vascular Pressor Responses in Treated and Untreated Essential Hypertension

1 reference

12 December 2020

Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure

1 reference

12 December 2020

A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension

1 reference

12 December 2020

Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.

1 reference

12 December 2020

Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

12 December 2020

Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial

1 reference

12 December 2020

A double-blind comparative study of doxazosin and prazosin when administered with β-blockers or diuretics

1 reference

12 December 2020

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

1 reference

12 December 2020

Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients

1 reference

12 December 2020

Doxazosin: alternative antihypertensive treatment

1 reference

12 December 2020

Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure.

1 reference

12 December 2020

Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.

1 reference

12 December 2020

The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: An in vitro study

1 reference

12 December 2020

Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.

1 reference

12 December 2020

Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients

1 reference

12 December 2020

Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group

1 reference

12 December 2020

Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man

1 reference

12 December 2020

Metabolic disturbances and antihypertensive therapy

1 reference

12 December 2020

1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting

1 reference

12 December 2020

Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity.

1 reference

12 December 2020

Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia

1 reference

12 December 2020

Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.

1 reference

12 December 2020

Doxazosin in 'resistant' hypertension.

1 reference

12 December 2020

An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency

1 reference

12 December 2020

Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.

1 reference

12 December 2020

Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin

1 reference

12 December 2020

The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockers

1 reference

12 December 2020

Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD

1 reference

12 December 2020

Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Clinical pharmacotherapeutics of doxazosin

1 reference

12 December 2020

Binding and functional properties of doxazosin in the human prostate adenoma and canine brain

1 reference

12 December 2020

Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study.

1 reference

12 December 2020

Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension

1 reference

12 December 2020

Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group

1 reference

12 December 2020

Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure

1 reference

12 December 2020

Effect of alpha 1-adrenoceptor blockade on maximal VO2 and endurance capacity in well-trained athletic hypertensive men

1 reference

12 December 2020

Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse

1 reference

12 December 2020

Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up

1 reference

12 December 2020

A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.

1 reference

12 December 2020

29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study

1 reference

12 December 2020

The pharmacokinetics of doxazosin in elderly normotensives

1 reference

12 December 2020

Effect of doxazosin on cholesterol synthesis in cell culture

1 reference

12 December 2020

Acute renal effects of doxazosin in man.

1 reference

12 December 2020

Treating hypertension and cardiovascular risk: are there trade-offs?

1 reference

12 December 2020

Preliminary results of the Norwegian doxazosin postmarketing surveillance study: A twelveweek experience

1 reference

12 December 2020

A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Doxazosin improves insulin sensitivity in hypertensive patients.

1 reference

12 December 2020

Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study

1 reference

12 December 2020

A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Doxazosin in the management of hypertensive diabetes--a cautionary note (?)

1 reference

12 December 2020

Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study

1 reference

12 December 2020

Factors influencing the lipid response to selective alpha 1-inhibition

1 reference

12 December 2020

Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol

1 reference

12 December 2020

Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin

1 reference

12 December 2020

Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: An ex vivo study

1 reference

12 December 2020

Doxazosin: a new alpha 1-adrenergic antagonist

1 reference

12 December 2020

Clinical pharmacology of doxazosin in patients with essential hypertension.

1 reference

12 December 2020

Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension

1 reference

12 December 2020

A clinical pharmacological assessment of doxazosin and enalapril in combination

1 reference

12 December 2020

Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study

1 reference

12 December 2020

Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison

1 reference

12 December 2020

Effects of doxazosin on serum lipids: A review of the clinical data and molecular basis for altered lipid metabolism

1 reference

12 December 2020

Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension

1 reference

12 December 2020

Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers

1 reference

12 December 2020

An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction. The Japanese Doxazosin Study Group

1 reference

12 December 2020

A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication

1 reference

12 December 2020

Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension

1 reference

12 December 2020

Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group

1 reference

12 December 2020

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

1 reference

12 December 2020

Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension

1 reference

12 December 2020

A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension

1 reference

12 December 2020

Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers.

1 reference

12 December 2020

Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.

1 reference

12 December 2020

Regression of Increased Left Ventricular Mass by Antihypertensives

1 reference

12 December 2020

A pharmacodynamic and pharmacokinetic assessment of a new alpha- adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects

1 reference

12 December 2020

Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.

1 reference

12 December 2020

Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia

1 reference

12 December 2020

Single-Dose and Steady-State Pharmacokinetics of Doxazosin Given in Combination with Chlorothiazide to Hypertensive Subjects

1 reference

12 December 2020

Pressor responsiveness in essential hypertension and the effects of treatment with an alpha blocker, calcium antagonist or ACE inhibitor

1 reference

12 December 2020

Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein

1 reference

12 December 2020

Coronary risk prediction in adults (the Framingham Heart Study)

1 reference

12 December 2020

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise

1 reference

12 December 2020

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

1 reference

12 December 2020

Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition

1 reference

12 December 2020

Influence of doxazosin on lipid transport in rats and hamsters

1 reference

12 December 2020

Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension

1 reference

12 December 2020

A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension

1 reference

12 December 2020

Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension

1 reference

12 December 2020

Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin

1 reference

12 December 2020

10.2165/00003495-199549020-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference